Neopharm Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of drugs for the treatment of cancer and other diseases. The Company built its drug development program around two technology platforms: a tumor-targeting toxin platform and NeoLipid liposomal drug delivery system. Neopharm has five drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis (IPF) and asthma.